|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0035668,
umls-concept:C0039194,
umls-concept:C0205263,
umls-concept:C0431085,
umls-concept:C0439859,
umls-concept:C0597032,
umls-concept:C0871261,
umls-concept:C1282910,
umls-concept:C1516044,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1881488,
umls-concept:C2911692
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2004-10-26
|
|
pubmed:abstractText |
B cell chronic lymphocytic leukemia (B-CLL) is a chronic leukemia manifested by increased numbers of B cells in circulation. The slow, smouldering nature of the disease in a significant proportion of the cases makes it an ideal target for immunotherapy. Dendritic cell (DC)-based immunotherapy is emerging as an exciting modality with significant clinical potential. In this study, three strategies for delivering antigens to DC, namely apoptotic bodies (Apo-DC), tumor lysates, and tumor RNA were studied in an autologous setting. In all six CLL patients, Apo-DC induced higher HLA-restricted, T cell responses than DC pulsed with tumor lysate or RNA. Real-time PCR confirmed higher expression of genes for IL-2 and IFN-gamma in T cells stimulated with Apo-DC. Concurrently, no IL-10 and low IL-4 responses indicated that the immune response was primarily of the Th1 type. Enzyme-linked immunospot assay revealed high IFN-gamma secretion by T cells when Apo-DC was used to stimulate autologous T cells in all patients. Our data suggest that cellular vaccines with DC loaded with apoptotic bodies may be a suitable approach for immunotherapy of B-CLL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Extracts,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class II,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-10,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-4,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0887-6924
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1810-5
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:15385926-Aged,
pubmed-meshheading:15385926-Antibodies, Monoclonal,
pubmed-meshheading:15385926-Antigens, Neoplasm,
pubmed-meshheading:15385926-Apoptosis,
pubmed-meshheading:15385926-Cell Extracts,
pubmed-meshheading:15385926-Dendritic Cells,
pubmed-meshheading:15385926-Female,
pubmed-meshheading:15385926-Histocompatibility Antigens Class I,
pubmed-meshheading:15385926-Histocompatibility Antigens Class II,
pubmed-meshheading:15385926-Humans,
pubmed-meshheading:15385926-Immunophenotyping,
pubmed-meshheading:15385926-Immunotherapy,
pubmed-meshheading:15385926-Interferon-gamma,
pubmed-meshheading:15385926-Interleukin-10,
pubmed-meshheading:15385926-Interleukin-2,
pubmed-meshheading:15385926-Interleukin-4,
pubmed-meshheading:15385926-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:15385926-Male,
pubmed-meshheading:15385926-RNA, Messenger,
pubmed-meshheading:15385926-RNA, Neoplasm,
pubmed-meshheading:15385926-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:15385926-T-Lymphocytes,
pubmed-meshheading:15385926-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:15385926-Th1 Cells
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL.
|
|
pubmed:affiliation |
Immune and Gene Therapy Lab., CCK, Karolinska Hospital, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
